Rubix LS combines investigator-led research with mobile clinical sites and advanced analytics to accelerate the development of treatments for rare diseases in underserved communities. By integrating real-world evidence and focusing on diverse patient data, the company aims to improve healthcare outcomes and bridge health equity gaps.
Funding
$1.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Rare diseases often lack effective treatments due to limited research, particularly within underserved communities that face barriers to accessing clinical trials and specialized care. Traditional clinical research struggles to engage diverse patient populations, resulting in data gaps and treatments that may not be optimized for all individuals.
Solution
Rubix LS accelerates the development of treatments for rare diseases by integrating investigator-led research with mobile clinical sites and advanced analytics, focusing on underserved communities. The company uses real-world evidence and diverse patient data to bridge health equity gaps and improve healthcare outcomes. Rubix LS combines investigator-initiated studies with contract research organization (CRO) services, offering expertise in preclinical research, early-phase clinical trials, data integration, and study management. By tailoring services to meet the needs of underserved populations, Rubix LS aims to conduct inclusive research that brings real-world value to every project.
Target Audience
The primary audience includes pharmaceutical, biotech, and life science companies, as well as federal agencies and health organizations seeking to accelerate rare disease research and improve health equity in underserved communities.
Features
- Mobile clinical sites/units to improve access to research for underserved communities.
- Advanced data analytics to transform complex data into actionable insights.
- Investigator-led research focused on addressing health equity gaps.
- Expertise in early-stage discovery, preclinical research, and early-phase clinical trials.
- Integration of real-world evidence to inform research approaches and patient engagement.
- Commitment to incorporating underserved patient data to provide a fuller picture of patient needs.